Oxford Centre for Haematology
Update in Myeloid Disorders: 21 Jan 2019, 9-1pm Oxford Belfry Hotel
Update in Aspects of Non-Malignant Haematology: 13 May 2019, 9-1pm Oxford Belfry Hotel
Update in Lymphoma: 24 June 2019, 9-1pm Oxford Belfry Hotel
Update in Myeloma and Plasma Cell Dycrasias: 30 Sept 2019, 9-1pm Oxford Belfry Hotel
The OCH Management Board has as members the Director of the OCH, the Head of Clinical Haematology, the Head of Laboratory Haematology, the Head of the Radcliffe Department of Medicine, the Head of the Nuffield Division of Clinical Laboratory Sciences, the Director of the MRC Molecular Haematology Unit, the Director of the MRC Human Immunology Unit, the RDM Research Strategy Coordinator and the Administrator of the OCH.
Quek L. et al, (2018), Nat med
Oudelaar AM. et al, (2018), Nat genet
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
MEAD AJ. et al, British journal of haematology
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A. et al, (2018), Blood, 132, 1225 - 1240
A tissue-specific self-interacting chromatin domain forms independently of enhancer-promoter interactions.
Brown JM. et al, (2018), Nat commun, 9